26.04.2018 SHOP APOTHEKE EUROPE N.V.  NL0012044747

DGAP-News: SHOP APOTHEKE EUROPE N.V.: Annual General Meeting welcomes European growth strategy.


 
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): AGM/EGM SHOP APOTHEKE EUROPE N.V.: Annual General Meeting welcomes European growth strategy. 26.04.2018 / 12:52 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN. SHOP APOTHEKE EUROPE N.V.: Annual General Meeting welcomes European growth strategy. * Review of the successful financial year 2017. * Agenda items approved by large majorities. Venlo, 26 April 2018. Today's Annual General Meeting of SHOP APOTHEKE EUROPE N.V. promoted the growth course of Europe's leading online pharmacy. A total of 58.66% of the share capital was represented. This corresponds to 7,051,450 shares. As part of their presentation, the members of the Management Board reviewed the financial year 2017 and gave a positive outlook for the financial year 2018 to the shareholders. The Annual General Meeting approved the agenda items proposed by the management with large majorities. Michael Köhler, CEO of SHOP APOTHEKE EUROPE N.V., comments: "The strong support by our shareholders is a valid confirmation of our success story, both operationally and strategically". After a compelling first quarter 2018, in which the Group more than doubled its sales volume compared to the same period last year, the Management Board has reaffirmed its ambitious growth targets for the current year. "We are targeting a further substantial revenue increase in 2018 and at the same time pursue our profitable growth guidance", CFO Dr. Ulrich Wandel adds. For the full year 2018, SHOP APOTHEKE EUROPE is budgeting an increase in group revenues of 87% to 97% to EUR 530 m to 560 m as well as a positive EBITDA (before one-off costs) at group level of EUR 0 to 2 m. Further information about the Annual General Meeting can be found in the Investor Relations section of the company's website www.shop-apotheke-europe.com. ABOUT SHOP APOTHEKE EUROPE. SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in Continental Europe. SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leading. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to about 2.8 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services. SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016. MEDIA CONTACTS. Trade and public media: Sven Schirmer Mobile: +49 152 28 50 63 61 Email: [email protected] Financial media: Thomas Schnorrenberg Mobile: +49 151 46 53 13 17 Email: [email protected] Investor Relations: Dr. Ulrich Wandel Telephone: +31 77 850 6117 Email: [email protected] DISCLAIMER. This publication is an advertisement. This communication constitutes neither an offer to sell nor a solicitation to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is not a securities prospectus. No public offering of any securities of Shop Apotheke Europe N.V. is being made. Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise. --------------------------------------------------------------------------- 26.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: SHOP APOTHEKE EUROPE N.V. Dirk Hartogweg 14 5928 LV Venlo Netherlands Phone: 0800 - 200 800 300 Fax: 0800 - 90 70 90 20 E-mail: [email protected] Internet: www.shop-apotheke-europe.com ISIN: NL0012044747, DE000A19Y072 WKN: A2AR94, A19Y07 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 679719 26.04.2018


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 283,99 539,71 701,01 968,06 1.060,32 1.204,35 1.798,76
EBITDA1,2 -12,14 -15,56 -18,58 15,20 -38,73 -29,66 39,99
EBITDA-Marge3 -4,27 -2,88 -2,65 1,57 -3,65 -2,46
EBIT1,4 -19,20 -28,73 -33,45 -0,87 -65,70 -69,17 -17,30
EBIT-Marge5 -6,76 -5,32 -4,77 -0,09 -6,20 -5,74 -0,96
Jahresüberschuss1 -21,36 -33,61 -36,27 -16,77 -74,19 -77,65 -11,61
Netto-Marge6 -7,52 -6,23 -5,17 -1,73 -7,00 -6,45 -0,65
Cashflow1,7 -23,24 -23,54 -30,37 17,80 11,64 -29,11 61,46
Ergebnis je Aktie8 -2,25 -2,79 -2,78 -1,17 -4,15 -4,32 -0,73
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Redcare Pharmacy
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2AR94 129,000 Halten 2.624,18
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
71,67 0,00 0,00 -61,78
KBV KCV KUV EV/EBITDA
5,03 42,70 1,46 69,72
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 17.04.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.04.2024 30.07.2024 05.11.2024 05.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-7,20% 5,98% -1,53% 44,94%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SHOP APOTHEKE EUROPE N.V.  ISIN: NL0012044747 können Sie bei EQS abrufen


E-Commerce , A2AR94 , RDC , XETR:RDC